These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31145704)

  • 21. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice.
    Hanudel MR; Chua K; Rappaport M; Gabayan V; Valore E; Goltzman D; Ganz T; Nemeth E; Salusky IB
    Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1369-F1377. PubMed ID: 27733366
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amelioration of chronic kidney disease-associated anemia by vadadustat in mice is not dependent on erythroferrone.
    Hanudel MR; Wong S; Jung G; Qiao B; Gabayan V; Zuk A; Ganz T
    Kidney Int; 2021 Jul; 100(1):79-89. PubMed ID: 33811979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease.
    Wolf M; White KE
    Curr Opin Nephrol Hypertens; 2014 Jul; 23(4):411-9. PubMed ID: 24867675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ironing out the cross talk between FGF23 and inflammation.
    David V; Francis C; Babitt JL
    Am J Physiol Renal Physiol; 2017 Jan; 312(1):F1-F8. PubMed ID: 27582104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase.
    Flamme I; Ellinghaus P; Urrego D; Krüger T
    PLoS One; 2017; 12(10):e0186979. PubMed ID: 29073196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glycerol-3-phosphate and fibroblast growth factor 23 regulation.
    Simic P; Babitt JL; Rhee EP
    Curr Opin Nephrol Hypertens; 2021 Jul; 30(4):397-403. PubMed ID: 33901058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of erythropoietin resistance and fibroblast growth factor 23 in dialysis patients: Results from the Japanese Dialysis Outcomes and Practice Patterns Study.
    Usui T; Zhao J; Fuller DS; Hanafusa N; Hasegawa T; Fujino H; Nomura T; Zee J; Young E; Robinson BM; Nangaku M
    Nephrology (Carlton); 2021 Jan; 26(1):46-53. PubMed ID: 32743932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibroblast growth factor-23: what we know, what we don't know, and what we need to know.
    Kovesdy CP; Quarles LD
    Nephrol Dial Transplant; 2013 Sep; 28(9):2228-36. PubMed ID: 23625971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The HIF-PHI BAY 85-3934 (Molidustat) Improves Anemia and Is Associated With Reduced Levels of Circulating FGF23 in a CKD Mouse Model.
    Noonan ML; Ni P; Agoro R; Sacks SA; Swallow EA; Wheeler JA; Clinkenbeard EL; Capitano ML; Prideaux M; Atkins GJ; Thompson WR; Allen MR; Broxmeyer HE; White KE
    J Bone Miner Res; 2021 Jun; 36(6):1117-1130. PubMed ID: 33592127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C-Terminal, but Not Intact, FGF23 and EPO Are Strongly Correlatively Elevated in Patients With Gain-of-Function Mutations in HIF2A: Clinical Evidence for EPO Regulating FGF23.
    Roszko KL; Brown S; Pang Y; Huynh T; Zhuang Z; Pacak K; Collins MT
    J Bone Miner Res; 2021 Feb; 36(2):315-321. PubMed ID: 33049075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epoetin Beta and C-Terminal Fibroblast Growth Factor 23 in Patients With Chronic Heart Failure and Chronic Kidney Disease.
    Eisenga MF; Emans ME; van der Putten K; Cramer MJ; Diepenbroek A; Velthuis BK; Doevendans PA; Verhaar MC; Joles JA; Bakker SJL; Nolte IM; Braam B; Gaillard CAJM
    J Am Heart Assoc; 2019 Aug; 8(16):e011130. PubMed ID: 31423921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Crosstalk of fibroblast growth factor 23 and anemia-related factors during the development and progression of CKD (Review).
    Zhang R; Wang SY; Yang F; Ma S; Lu X; Kan C; Zhang JB
    Exp Ther Med; 2021 Oct; 22(4):1159. PubMed ID: 34504604
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Associations among erythropoietic, iron-related, and FGF23 parameters in pediatric kidney transplant recipients.
    Limm-Chan B; Wesseling-Perry K; Pearl MH; Jung G; Tsai-Chambers E; Weng PL; Hanudel MR
    Pediatr Nephrol; 2021 Oct; 36(10):3241-3249. PubMed ID: 33903951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Aspects of the Kidney in the Regulation of Fibroblast Growth Factor 23 (FGF23) and Mineral Homeostasis.
    Mace ML; Olgaard K; Lewin E
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Segregating the effects of ferric citrate-mediated iron utilization and FGF23 in a mouse model of CKD.
    Liesen MP; Noonan ML; Ni P; Agoro R; Hum JM; Clinkenbeard EL; Damrath JG; Wallace JM; Swallow EA; Allen MR; White KE
    Physiol Rep; 2022 Jun; 10(11):e15307. PubMed ID: 35656701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF.
    Wheeler JA; Clinkenbeard EL
    Curr Mol Biol Rep; 2019 Mar; 5(1):8-17. PubMed ID: 31218207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Saccharated ferric oxide attenuates haematopoietic response induced by epoetin beta pegol in patients undergoing haemodialysis.
    Iwasaki T; Fujimori A; Nakanishi T; Okada S; Hanawa N; Hasuike Y; Kuragano T
    BMC Nephrol; 2021 Apr; 22(1):124. PubMed ID: 33832448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M; Koch TA; Bregman DB
    J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interconnections of fibroblast growth factor 23 and klotho with erythropoietin and hypoxia-inducible factor.
    Afsar B; Kanbay M; Afsar RE
    Mol Cell Biochem; 2022 Jul; 477(7):1973-1985. PubMed ID: 35381946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
    Iguchi A; Yamamoto S; Yamazaki M; Tasaki K; Suzuki Y; Kazama JJ; Narita I
    Clin Exp Nephrol; 2018 Aug; 22(4):789-796. PubMed ID: 29181658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.